Olmetab
Generic Name
Olmesartan Medoxomil
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab 40 mg tablet | ৳ 7.00 | ৳ 70.00 |
Description
Overview of the medicine
Olmetab 40 mg tablet contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily and thereby lowering blood pressure. It may also be used to reduce the risk of cardiovascular events in certain patients.
Uses & Indications
Dosage
Adults
The recommended starting dose is 20 mg orally once daily. The dose may be increased to 40 mg once daily if blood pressure is not adequately controlled after 2 weeks.
Elderly
No initial dose adjustment is generally necessary for elderly patients with normal renal function. For those with possible volume depletion, consider a lower starting dose.
Renal_impairment
For patients with moderate renal impairment (creatinine clearance 20-60 mL/min), a starting dose of 20 mg once daily is recommended, with careful monitoring. Not recommended for severe renal impairment (creatinine clearance <20 mL/min).
How to Take
Take Olmetab orally once daily, with or without food. Swallow the tablet whole with a glass of water. It is recommended to take it at the same time each day to maintain consistent blood levels.
Mechanism of Action
Olmesartan Medoxomil is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This leads to vasodilation and reduced blood pressure.
Pharmacokinetics
Onset
The antihypertensive effect is usually evident within 2 weeks, with the maximum effect generally achieved within 4-8 weeks of starting treatment.
Excretion
Approximately 35-50% of the absorbed dose is excreted renally (via urine), and the remainder is eliminated via the bile into feces.
Half life
The elimination half-life of olmesartan is approximately 13 hours.
Absorption
Olmesartan Medoxomil is a prodrug that is rapidly and completely converted to the active compound olmesartan during absorption from the gastrointestinal tract. The absolute bioavailability of olmesartan is about 26%. Peak plasma concentrations of olmesartan are reached in about 1-2 hours after oral administration.
Metabolism
Olmesartan Medoxomil is completely hydrolyzed to olmesartan. Olmesartan is not further metabolized and is not a substrate of cytochrome P450 enzymes.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters) due to risk of fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity. Monitor lithium levels carefully.
Aliskiren
Contraindicated in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²) due to increased risk of hyperkalemia, hypotension, and renal impairment.
Colesevelam
Concomitant administration may reduce the systemic exposure and peak plasma concentration of olmesartan. Administer Olmetab at least 4 hours before Colesevelam.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal function deterioration, including acute renal failure, especially in elderly or volume-depleted patients.
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive. If ingestion is recent, induce emesis or perform gastric lavage. Administer activated charcoal to reduce absorption. Intravenous fluids and vasopressors may be used to manage hypotension.
Pregnancy & Lactation
Olmetab is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury and death. It should be discontinued as soon as pregnancy is detected. It is unknown whether olmesartan is excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or the drug, considering the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters) due to risk of fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity. Monitor lithium levels carefully.
Aliskiren
Contraindicated in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²) due to increased risk of hyperkalemia, hypotension, and renal impairment.
Colesevelam
Concomitant administration may reduce the systemic exposure and peak plasma concentration of olmesartan. Administer Olmetab at least 4 hours before Colesevelam.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal function deterioration, including acute renal failure, especially in elderly or volume-depleted patients.
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive. If ingestion is recent, induce emesis or perform gastric lavage. Administer activated charcoal to reduce absorption. Intravenous fluids and vasopressors may be used to manage hypotension.
Pregnancy & Lactation
Olmetab is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury and death. It should be discontinued as soon as pregnancy is detected. It is unknown whether olmesartan is excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or the drug, considering the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the date of manufacture, depending on the manufacturer's specification.
Availability
Pharmacies, hospitals
Approval Status
Approved
Patent Status
Generic available (Patent expired)
Clinical Trials
Olmesartan Medoxomil has been extensively studied in various clinical trials, including the ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention) trial, which investigated its role in preventing microalbuminuria in diabetic patients, and studies confirming its efficacy in reducing blood pressure and cardiovascular events in hypertensive patients.
Lab Monitoring
- Monitor blood pressure regularly.
- Check serum electrolytes, especially potassium levels, periodically.
- Assess renal function (BUN, serum creatinine, GFR) at baseline and periodically during therapy, particularly in patients with pre-existing renal impairment or those receiving concomitant diuretics.
- Monitor liver function tests if clinically indicated.
Doctor Notes
- Emphasize the importance of consistent daily dosing and adherence to therapy.
- Regularly monitor blood pressure, renal function, and serum potassium, especially when initiating therapy or titrating the dose, and in high-risk patients.
- Counsel patients on potential side effects like dizziness and the importance of reporting severe symptoms like angioedema or severe diarrhea.
- Strongly advise female patients of childbearing age about the fetal toxicity risk and the need to discontinue the drug if pregnancy is planned or detected.
Patient Guidelines
- Take this medicine exactly as prescribed by your doctor, usually once daily.
- Do not stop taking Olmetab suddenly without consulting your doctor, as this may lead to a sudden increase in blood pressure.
- Inform your doctor about all other medications, supplements, and herbal products you are taking.
- Avoid potassium supplements or salt substitutes containing potassium unless specifically advised by your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmetab may cause dizziness or lightheadedness, especially when starting treatment or increasing the dose. Patients should be cautioned about operating machinery or driving until they know how Olmetab affects them and are certain they can perform such activities safely.
Lifestyle Advice
- Maintain a healthy diet, low in sodium and saturated fats.
- Engage in regular physical activity as recommended by your doctor.
- Maintain a healthy body weight.
- Limit alcohol consumption and avoid smoking to help control blood pressure.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmetab Brand
Other medicines available under the same brand name
